What is the difference between Lonhala Magnair and Seebri Neohaler?

The primary difference between Lonhala Magnair and Seebri Neohaler is the dosage form and how they are administered to the patient.

Lonhala Magnair is delivered as a nebulized solution for inhalation via the Magnair nebulizer. The Seebri Neohaler consists of dry-powder inhalation capsules placed into a hand-held device and inhaled.

Both products are prescription treatments from Sunovion Pharmaceuticals that contain glycopyrrolate, an anticholinergic, long-acting muscarinic antagonist (LAMA) bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) of the lung, including chronic bronchitis and/or emphysema.

How is Lonhala Magnair given?

The Lonhala Magnair technology was developed to allow a quiet, portable, closed system nebulizer that can deliver glycopyrrolate in 2 to 3 minutes with normal breathing while using the device. Each 1 mL unit-dose vial of the Lonhala Magnair aqueous solution contains 25 mcg of glycopyrrolate. The Seebri Neohaler consists of capsules that contain 15.6 mcg of glycopyrrolate and the hand-held inhalation device; the capsules are used in the device and not taken by mouth. Both products are used twice daily (in the morning and evening) at the same time every day.